Benitec Biopharma Limited (NASDAQ:BNTC) Receives Consensus Recommendation of "Buy" from Brokerages

Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report) has earned an average rating of "Buy" from the nine brokerages that are currently covering the company, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $23.83.

Several research analysts have recently commented on the company. JMP Securities reissued a "market outperform" rating and set a $20.00 price objective on shares of Benitec Biopharma in a report on Thursday, May 15th. HC Wainwright reissued a "buy" rating and set a $28.00 price objective on shares of Benitec Biopharma in a report on Monday, May 19th.

Benitec Biopharma Trading Down 2.2%

Shares of BNTC opened at $14.61 on Monday. The business's 50-day moving average price is $14.42 and its 200-day moving average price is $12.88. Benitec Biopharma has a twelve month low of $6.66 and a twelve month high of $17.15. The stock has a market cap of $383.51 million, a PE ratio of -9.68 and a beta of 0.44. The company has a quick ratio of 14.80, a current ratio of 14.80 and a debt-to-equity ratio of 0.01.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.12. On average, equities analysts forecast that Benitec Biopharma will post -1.48 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Suvretta Capital Management, L bought 900,000 shares of the business's stock in a transaction on Wednesday, March 26th. The stock was acquired at an average price of $13.00 per share, with a total value of $11,700,000.00. Following the completion of the purchase, the director now directly owns 8,793,245 shares in the company, valued at $114,312,185. This represents a 11.40% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 1.30% of the stock is owned by insiders.

Institutional Trading of Benitec Biopharma

Several hedge funds and other institutional investors have recently bought and sold shares of BNTC. Franklin Resources Inc. raised its holdings in shares of Benitec Biopharma by 269.0% during the fourth quarter. Franklin Resources Inc. now owns 2,939,287 shares of the biotechnology company's stock valued at $37,123,000 after acquiring an additional 2,142,643 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of Benitec Biopharma by 198.5% during the fourth quarter. Janus Henderson Group PLC now owns 2,616,427 shares of the biotechnology company's stock valued at $33,268,000 after acquiring an additional 1,739,904 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in shares of Benitec Biopharma by 134.4% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,972,524 shares of the biotechnology company's stock valued at $24,913,000 after acquiring an additional 1,131,129 shares in the last quarter. Infinitum Asset Management LLC raised its holdings in shares of Benitec Biopharma by 435.7% during the first quarter. Infinitum Asset Management LLC now owns 1,125,000 shares of the biotechnology company's stock valued at $14,636,000 after acquiring an additional 915,000 shares in the last quarter. Finally, Suvretta Capital Management LLC raised its holdings in shares of Benitec Biopharma by 1.5% during the fourth quarter. Suvretta Capital Management LLC now owns 8,960,009 shares of the biotechnology company's stock valued at $113,165,000 after acquiring an additional 130,956 shares in the last quarter. Institutional investors own 52.19% of the company's stock.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.